Switch to a single dose of aflibercept in bevacizumab nonresponders with AMD

Canadian Journal of Ophthalmology

Volumn 49, Issue 5, 2014, Pages 431-435

  Michalewski, Janusz ^a,b   Nawrocki, Jerzy ^a,b   Trębińska, Magdalena ^b   Michalewska, Zofia ^a,b  

^a Ophthalmic Clinic Jasne Blonia   (Poland)

^b Dr K Jonscher   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTIBIOTIC AGENT; BEVACIZUMAB; LANTHANUM; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN RECEPTOR;

AGE RELATED MACULAR DEGENERATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERVENTION STUDY; INTRARETINAL FLUID; MALE; OPTICAL COHERENCE TOMOGRAPHY DEVICE; OUTCOME ASSESSMENT; PHOTORECEPTOR; RETINA EDEMA; RETROSPECTIVE STUDY; SCANNING LASER OPHTHALMOSCOPY; SINGLE DRUG DOSE; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; VISUAL ACUITY; VISUAL ACUITY CHART; AGED; DRUG EFFECTS; DRUG RESISTANCE; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; RETINA; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG RESISTANCE; DRUG SUBSTITUTION; FEMALE; HUMANS; INTERVENTION STUDIES; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84922363772     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2014.07.012     Document Type: Article

References (15)

1. Brown DM,MichelsM,KaiserPK,etal.Ranibizumabversus verteporfin photodynamictherapyforneovascularage-relatedmac-ular degeneration:two-yearresultsoftheANCHORstudy. Oph-thalmology. 2009;116:57-65.
2. Lalwani GA,RosenfeldPJ,FungAE,etal.Avariable-dosing regimen withintravitrealranibizumabforneovascularage-related macular degeneration:year2ofthePrONTOstudy. Am J Ophthalmol. 2009;148:43-58.
3. Krebs I,GlittenbergC,Ansari-ShahrezaeiS,HagenS,SteinerI, Binder S.Non-responderstotreatmentwithantagonistsofvascular endothelial growthfactorinage-relatedmaculardegeneration. Br J Ophthalmol. 2013;97:1443-6.
4. Otsuji T,NagaiY,ShoK,etal.Initialnon-respondersto ranibizumab inthetreatmentofage-relatedmaculardegeneration (AMD). Clin Ophthalmol. 2013;7:1487-90.
5. The CATTResearchGroup.Ranibizumabandbevacizumabfor neovascular age-relatedmaculardegeneration. N EnglJMed. 2011;364:1897-908.
6. Stewart MW,RosenfeldPJ,PenhaFM,etal.Pharmacokinetic rationale fordosingevery2weeksversus4weekswithintravitreal ranibizumab, bevacizumab,andaflibercept (vascularendothelial growth factorTrap-eye). Retina. 2012;32:434-57.
7. Fung AT,KumarN,VanceSK,etal.Pilotstudytoevaluatetherole of high-doseranibizumab2.0mginthemanagementofneovascular age-related maculardegenerationinpatientswithpersistent/recur-rent macular fluid, 30daysfollowingtreatmentwithintravitreal anti-VEGF therapy(theLASTStudyEye (Lond). 2012;26:1181-7.
8. Busbee BG,HoAC,BrownDM,etal.HARBORStudyGroup. Twelve-month efficacy andsafetyof0.5mgor2.0mgranibizumab in patientswithsubfovealneovascularage-relatedmaculardegener-ation. Ophthalmology. 2013;120:1046-56.
9. Schmidt-Erfurth U,KaiserPK,KorobelnikJF,etal.Intravitreal aflibercept injectionforneovascularage-relatedmaculardegenera-tion ninety-sixweekresultsoftheVIEWstudies. Ophthalmology. 2014;21:193-201.
10. Heier JS,BrownDM,ChongV,etal.VIEW1andVIEW2Study Groups. Intravitrealaflibercept (VEGFTrap-Eye)inwetage-related macular degeneration. Ophthalmology. 2012;119:2537-48.
11. Chang AA,LiH,BroadheadGK,etal.Intravitrealaflibercept for treatment-resistant neovascularage-relatedmaculardegeneration. Ophthalmology. 2014Jan;121:188-92.
12. Kumar N,MarsigliaM,MrejenS,etal.Visualandanatomical outcomes ofintravitrealaflibercept ineyeswithpersistentsubfoveal fluid despiteprevioustreatmentswithranibizumabinpatientswith neovascular age-relatedmaculardegeneration. Retina. 2013;33: 1605-12.
13. Bakall B,FolkJC,BoldtHC,etal.Aflibercept therapyforexudative age-related maculardegenerationresistanttobevacizumaband ranibizumab. Am JOphthalmol. 2013;156:15-22.
14. Ho VY,YehS,OlsenTW,etal.Short-termoutcomesofaflibercept for neovascularage-relatedmaculardegenerationineyespreviously treated withothervascularendothelialgrowthfactorinhibitors. Am J Ophthalmol. 2013;156:23-8.
15. Yonekawa Y,AndreoliC,MillerJB,etal.Conversiontoaflibercept for chronicrefractoryorrecurrentneovascularage-relatedmacular degeneration. Am JOphthalmol. 2013;156:29-35.